An inhibitor of catechol-o-methyltransferase (COMT) used as an adjunct to carbidopa-levodopa therapy in the treatment of parkinson’s disease for patients who experience the signs and symptoms of end-of-dose “wearing-off.” Entacapone primarily inhibits the peripheral metabolism of levodopa by COMT, allowing greater and more sustained levels of levodopa to penetrate the brain, where it can be converted to dopamine. Marketed under the brand name comtan.
A drug used to treat Parkinson disease. Entacapone (Comtan) is used along with Levodopa and carbidopa to treat Parkinson disease because it increases levels of levodopa in the blood, which helps more of the drug get into the brain.